HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

HDT Bio, a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics Against Diverse Emerging Infectious Threats), a national consortium led by Albert Einstein College of Medicine and funded by the National Institute of Allergy and Infectious Diseases as part of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness Network.